Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 261.43 Billion KRW | -3.2% |
| 2022 | 270.08 Billion KRW | 20.18% |
| 2021 | 224.72 Billion KRW | 21.1% |
| 2020 | 185.56 Billion KRW | 25.0% |
| 2019 | 148.45 Billion KRW | 16.35% |
| 2018 | 127.59 Billion KRW | 22.29% |
| 2017 | 104.33 Billion KRW | 6.19% |
| 2016 | 98.26 Billion KRW | 9.2% |
| 2015 | 89.98 Billion KRW | 19.6% |
| 2014 | 75.23 Billion KRW | 5.74% |
| 2013 | 71.15 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 337.36 Billion KRW | 20.9% |
| 2024 Q1 | 279.04 Billion KRW | 6.74% |
| 2023 Q2 | 279.06 Billion KRW | -0.68% |
| 2023 Q1 | 280.98 Billion KRW | 4.04% |
| 2023 FY | 261.43 Billion KRW | -3.2% |
| 2023 Q4 | 261.43 Billion KRW | -6.69% |
| 2023 Q3 | 280.16 Billion KRW | 0.4% |
| 2022 Q3 | 270.57 Billion KRW | -0.8% |
| 2022 Q2 | 272.75 Billion KRW | 10.43% |
| 2022 FY | 270.08 Billion KRW | 20.18% |
| 2022 Q1 | 247 Billion KRW | 9.91% |
| 2022 Q4 | 270.08 Billion KRW | -0.18% |
| 2021 Q1 | 187.9 Billion KRW | 1.26% |
| 2021 Q4 | 224.72 Billion KRW | 0.52% |
| 2021 FY | 224.72 Billion KRW | 21.1% |
| 2021 Q3 | 223.56 Billion KRW | 11.27% |
| 2021 Q2 | 200.91 Billion KRW | 6.92% |
| 2020 Q2 | 163.84 Billion KRW | -3.34% |
| 2020 Q3 | 180.92 Billion KRW | 10.43% |
| 2020 FY | 185.56 Billion KRW | 25.0% |
| 2020 Q1 | 169.5 Billion KRW | 14.18% |
| 2020 Q4 | 185.56 Billion KRW | 2.56% |
| 2019 FY | 148.45 Billion KRW | 16.35% |
| 2019 Q1 | 145.94 Billion KRW | 14.39% |
| 2019 Q4 | 148.45 Billion KRW | -8.85% |
| 2019 Q3 | 162.86 Billion KRW | 3.6% |
| 2019 Q2 | 157.19 Billion KRW | 7.71% |
| 2018 Q2 | 137.59 Billion KRW | 20.69% |
| 2018 FY | 127.59 Billion KRW | 22.29% |
| 2018 Q4 | 127.59 Billion KRW | -2.11% |
| 2018 Q3 | 130.34 Billion KRW | -5.27% |
| 2018 Q1 | 114.01 Billion KRW | 9.27% |
| 2017 FY | 104.33 Billion KRW | 6.19% |
| 2017 Q4 | 104.33 Billion KRW | 0.0% |
| 2016 Q2 | 105.25 Billion KRW | 1.57% |
| 2016 Q1 | 103.63 Billion KRW | 15.17% |
| 2016 FY | 98.26 Billion KRW | 9.2% |
| 2016 Q3 | 103.01 Billion KRW | -2.13% |
| 2015 Q2 | 85.81 Billion KRW | 7.83% |
| 2015 Q4 | 89.98 Billion KRW | 1.39% |
| 2015 Q1 | 79.58 Billion KRW | 5.78% |
| 2015 Q3 | 88.75 Billion KRW | 3.42% |
| 2015 FY | 89.98 Billion KRW | 19.6% |
| 2014 Q2 | 80.2 Billion KRW | -0.4% |
| 2014 Q1 | 80.52 Billion KRW | 0.0% |
| 2014 Q3 | 83.44 Billion KRW | 4.04% |
| 2014 FY | 75.23 Billion KRW | 5.74% |
| 2014 Q4 | 75.23 Billion KRW | -9.83% |
| 2013 FY | 71.15 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -492.116% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | -121.83% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | -186.764% |
| HANDOK Inc. | 94.46 Billion KRW | -176.751% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -1130.667% |
| Yuhan Corporation | 284.75 Billion KRW | 8.192% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | -124.765% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -1507.952% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 9.481% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -707.283% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -323.545% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -1242.255% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -763.374% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -440.737% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -492.116% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -736.829% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -643.202% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -443.199% |
| JW Holdings Corporation | 147.58 Billion KRW | -77.134% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | -208.935% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -146.421% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -384.822% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -868.338% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -704.123% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | -138.168% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -492.116% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | -38.586% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | -8.233% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -146.421% |
| Yuhan Corporation | 284.75 Billion KRW | 8.192% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | -108.678% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -321.755% |
| Suheung Co., Ltd. | 259.84 Billion KRW | -0.612% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -146.421% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | -228.42% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -431.992% |
| CKD Bio Corp. | 69.08 Billion KRW | -278.436% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | -148.798% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | -269.791% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -383.614% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -384.822% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | -34.229% |
| Boryung Corporation | 189.8 Billion KRW | -37.736% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -360.01% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -323.545% |
| JW Lifescience Corporation | 23.39 Billion KRW | -1017.297% |